Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2025 · 10-Q
Revenue$8.29M$8.29M−8.7% vs Q3 2024 Net Income-$1.94M-$1.94MN/M vs Q3 2024 EPS Diluted-$0.13-$0.13N/M vs Q3 2024 Operating Income-$1,965,260N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$163,392−64.5% Margins · derivedOperating margin-23.7%−5.1 pt vs Q3 2024
Net margin-23.4%−6.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 7, 2025 · 38 d after period end